Respiratory

Latest News

Nerandomilast is an investigational oral, preferential inhibitor of phosphodiesterase 4B that has shown promise in IPF and PPF. | Image credit: Елена Бутусова - stock.adobe.com
Nerandomilast Improves Lung Function in Progressive Pulmonary Fibrosis: FIBRONEER-ILD

February 13th 2025

Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline at 52 weeks in the phase 3 FIBRONEER-ILD trial.

Sanofi | Image credit: Eagle - stock.adobe.com
Combination Influenza and COVID-19 Vaccine Candidates Granted Fast Track Designation

December 16th 2024

Group of diverse kids | Image Credit: © EKKAPON-stock.adobe.com
Ambient Toxins Linked to Disabilities in Minority Schoolchildren

December 10th 2024

RSV vaccine | Image credit: Pawel - atock.adobe.com
Nirsevimab Protected Infants, Children From Severe RSV in 2023–2024 Season

December 6th 2024

Doctor with an image of lungs | Image credit: lungs_PRASANNAPIX
Key Flu and RSV Recommendations for the 2024-2025 Respiratory Virus Season

November 26th 2024

Continuing Medical Education
View All
April 25th 2025

Managing Patients With COPD: Evidence-Based Care and Optimizing Value of New and Emerging Targeted Therapies

1.0 Credit / Immunology, Pulmonology/Respiratory

More News

Flavorants and Propylene Glycol From e-Cigarettes Form Harmful Irritants When Combined
November 2nd 2018

Flavorants and Propylene Glycol From e-Cigarettes Form Harmful Irritants When Combined

David Bai
The mixture of flavorants and propylene glycol (PG) in electronic cigarettes (e-cigs) leads to the formation of acetals that have been shown to activate irritation receptors, predisposing users to the same potential dangers as using traditional cigarettes, a new study said.
Electronic Cigarettes May Cause Same Lung Injuries, Respiratory Changes as Classic Cigarettes
October 26th 2018

Electronic Cigarettes May Cause Same Lung Injuries, Respiratory Changes as Classic Cigarettes

David Bai, PharmD
Electronic cigarettes can cause detrimental effects to human health and should be reconsidered as a smoking cessation tool, based on results from a recent study.
Study Evaluates Healthcare Utilization and Expenditures for Patients With NTM
October 25th 2018

Study Evaluates Healthcare Utilization and Expenditures for Patients With NTM

Alison Rodriguez
Patients with nontuberculous mycobacterial lung disease (NTMLD) have a significant greater risk of hospitalization and higher total healthcare expenditures than matched control patients without NTMLD.
Second Biologic to Make Entry for Moderate-to-Severe Asthma
October 24th 2018

Second Biologic to Make Entry for Moderate-to-Severe Asthma

Allison Inserro
The FDA’s approval of dupilumab, already approved for severe eczema, for asthma makes it the second biologic for the incurable lung disease.
Muscle Relaxants During Anesthesia May Increase Risk of Postoperative Pulmonary Complications
October 20th 2018

Muscle Relaxants During Anesthesia May Increase Risk of Postoperative Pulmonary Complications

Alison Rodriguez
Neuromuscular blocking agents, or muscle relaxants, are often used in surgery to prevent muscles from moving when a patient is unconscious. A recent study found that the use of neuromuscular blockers during general anesthesia is associated with an increased risk of postoperative pulmonary complications.
Dupilumab Shows Positive Results for Chronic Rhinosinusitis With Nasal Polyps
October 17th 2018

Dupilumab Shows Positive Results for Chronic Rhinosinusitis With Nasal Polyps

Allison Inserro
With a decision from the FDA for its use in moderate-to-severe asthma expected by the end of the week, the biologic dupilumab showed positive results from a pivotal phase 3 trial for inadequately controlled chronic rhinosinusitis with nasal polyps.
FDA Label Rule Change Gives Prescribers More Detail for Pregnant Women With Asthma
October 17th 2018

FDA Label Rule Change Gives Prescribers More Detail for Pregnant Women With Asthma

David Bai, PharmD
Treating lung conditions like asthma in pregnant women is a challenge, as it requires knowledge of both the safety of treatments during pregnancy as well as understanding the risks of the disease for both the woman and the infant, noted a review of a new Food and Drug Administration (FDA) information system for prescribers.
FDA Inquiring If Some e-Cigarette Makers Are Selling Devices Without Approval
October 13th 2018

FDA Inquiring If Some e-Cigarette Makers Are Selling Devices Without Approval

Allison Inserro
The FDA said Friday it is asking 21 e-cigarette companies for more information about whether more than 40 products, including some flavored e-cigarette products, are being illegally marketed and are outside the agency’s current compliance policy. The move comes a month after the agency warned of a teen vaping epidemic and said it would be cracking down on the sale of the devices to kids.
FDA Approves Arikayce to Treat Certain Patients With Rare Lung Disease
October 11th 2018

FDA Approves Arikayce to Treat Certain Patients With Rare Lung Disease

Alison Rodriguez
The first drug specifically to treat patients with Mycobacterium avium complex, a rare and chronic lung disease, has been approved by the FDA. Arikayce is also the first drug to be approved under the Limited Population Pathway for Antibacterial and Antifungal Drugs, established under the 21st Century Cures Act.
Tackling Antibiotic Prescribers' Behaviors for Respiratory Infections at the VA
October 5th 2018

Tackling Antibiotic Prescribers' Behaviors for Respiratory Infections at the VA

Allison Inserro
An audit feedback intervention is an approach used to help providers translate evidence into behavior change, and at ID Week, 1 abstract showed that it helped reduce antibiotic prescribing for acute respiratory infections (ARIs). Another report showed that antibiotic prescribing rates for ARIs at medical centers operated by the Department of Veterans Affairs (VA) have steadily declined since 2010. ID Week is an annual conference focused on many different infectious disease topics.
Study Finds Gaps in Medicaid Coverage Guidelines for Asthma Care
October 5th 2018

Study Finds Gaps in Medicaid Coverage Guidelines for Asthma Care

Alison Rodriguez
A study found a lack of consistent and comprehensive coverage throughout the country, identified coverage-related challenges to accessing asthma care within states, and found substantial gaps between guidelines-based asthma care and coverage by state Medicaid programs.
What We're Reading: Demand for Antibiotics; FDA Inspects Juul; Fast Food Consumption
October 3rd 2018

What We're Reading: Demand for Antibiotics; FDA Inspects Juul; Fast Food Consumption

AJMC Staff
Patients who receive an antibiotic prescription report being happiest with their doctor’s visit, whether or not they needed the antibiotic; the FDA has collected more than 1000 pages of documents from Juul’s headquarters as part of a surprise inspection into its sales and marketing practices; on any given day, an average of 36.6% of American adults are eating fast food, and the proportion eating fast food increases with income.
Patients Taking Inhaled Steroids May Be at Greater Risk for NTM
September 28th 2018

Patients Taking Inhaled Steroids May Be at Greater Risk for NTM

Alison Rodriguez
Patients who use inhaled steroids to control their asthma or other breathing problems may be at a greater risk for developing nontuberculous mycobacterial lung infections.
The New Era of Telemedicine Brings Positive Health Outcomes for Patients With Asthma
September 28th 2018

The New Era of Telemedicine Brings Positive Health Outcomes for Patients With Asthma

David Bai
A recent meta-analysis shows that combined telemedicine involving telecase management or teleconsultation has significant improvements in asthma control and quality of life.
Draft ICER Report Finds Some Benefit for 5 Biologics to Treat Severe Asthma
September 25th 2018

Draft ICER Report Finds Some Benefit for 5 Biologics to Treat Severe Asthma

Allison Inserro
The Institute for Clinical and Economic Review (ICER) found enough evidence that biologics provide a benefit over the usual standard of care for patients with moderate to severe asthma, the organization said in a draft evidence report released Tuesday. However, since biologics cost much more than other pharmaceutical treatments, ICER said the 5 drugs it reviewed did not meet its usual cost-effectiveness thresholds.
Embarrassment Contributes to Poor Asthma Treatment Adherence, Study Finds
September 22nd 2018

Embarrassment Contributes to Poor Asthma Treatment Adherence, Study Finds

Alison Rodriguez
Despite there being effective therapies, asthma is commonly poorly controlled. Acknowledging and addressing patient treatment beliefs and perceptual barriers to adherence to asthma medication is necessary for designing adherence interventions for patients.
Patients With Asthma–COPD Overlap Have More Severe Disease, Study Finds
September 18th 2018

Patients With Asthma–COPD Overlap Have More Severe Disease, Study Finds

David Bai
Researchers pinpointed the characteristics of asthma-chronic obstructive pulmonary disease (COPD) overlap (ACO) causing a greater disease burden than either condition alone.
Associations Between Perceptions of Community Safety With Respiratory Illness Among Low-Income Adults
September 16th 2018

Associations Between Perceptions of Community Safety With Respiratory Illness Among Low-Income Adults

Alison Rodriguez
There is an association between an individual’s perceptions of community safety and adverse respiratory health among populations with exposure to high air pollution, according to new research.
Study Identifies Benralizumab Responders Among COBRA Participants With Severe Asthma
September 12th 2018

Study Identifies Benralizumab Responders Among COBRA Participants With Severe Asthma

David Bai
A retrospective analysis of data from patients with severe asthma who participated in the COBRA trial identified key clinical characteristics that may help clinicians recognize patients who may benefit from additional targeted drug therapy, such as benralizumab.
GSK's Nucala Comes Out Ahead in Comparison of Cinqair, Fasenra, Study Says
September 10th 2018

GSK's Nucala Comes Out Ahead in Comparison of Cinqair, Fasenra, Study Says

Allison Inserro
In an indirect treatment comparison of 3 drugs for severe eosinophilic asthma, GlaxoSmithKline’s (GSK) mepolizumab, marketed as Nucala, reduced exacerbations by 34% to 45% compared with reslizumab or benralizumab. The results were published in The Journal of Allergy and Clinical Immunology.
Genetic Profile and Proximity to Roadways Affect Asthma Symptoms, Study Finds
September 9th 2018

Genetic Profile and Proximity to Roadways Affect Asthma Symptoms, Study Finds

Alison Rodriguez
Patients with asthma with certain genotype combinations demonstrate more intense symptoms when combined with a close proximity to roadways, suggesting that traffic-related air pollution exposure may affect the likelihood of asthma diagnosis and exacerbations.
Security Check Trays Pose Highest Risk of Spreading Respiratory Viruses in Airports
September 7th 2018

Security Check Trays Pose Highest Risk of Spreading Respiratory Viruses in Airports

Laura Joszt, MA
Airports provide multiple sites of risk to contract respiratory viruses, with plastic security screening trays posing the highest potential risk, according to new research published in BMC Infectious Diseases.
Intensive Care Unit Usage for Pneumonia Doubles Length of Hospital Stay
September 6th 2018

Intensive Care Unit Usage for Pneumonia Doubles Length of Hospital Stay

David Bai
A recently released report using data from the National Hospital Care Survey (NHCS) verifies existing data on the prevalence of pneumonia in hospitalizations and emergency department (ED) visits and provides the first-ever data collection on diagnostic testing, length of stay (LOS), intensive care unit (ICU) stays, and mortality.
E-Cigarette Use Prevalent Among Men, People With Comorbidities, Survey Finds
August 31st 2018

E-Cigarette Use Prevalent Among Men, People With Comorbidities, Survey Finds

David Bai
E-cigarette use in the United States is more prevalent in people who are younger, have comorbid conditions, or are former or current conventional cigarette smokers, according to results from a recent Behavioral Risk Factor Surveillance System national report.
Study: Prescribers Unaware of Comorbidity of Nonselective Beta Blockers for Patients With COPD or Asthma
August 30th 2018

Study: Prescribers Unaware of Comorbidity of Nonselective Beta Blockers for Patients With COPD or Asthma

Alison Rodriguez
A substantial number of prescribers did not regard nonselective beta blockers as contraindicated, suggesting the need for improvement programs that target the prescribers’ awareness and knowledge.
Health Organizations React to Rollback of Clean Power Plan Rules
August 22nd 2018

Health Organizations React to Rollback of Clean Power Plan Rules

Allison Inserro
Health organizations reacted with dismay at the decision by the Environmental Protection Agency to reverse the Clean Power Plan, which set limits on coal-fired power plants, and replace it with one called the Affordable Clean Energy Rule, which gives more authority to states in an effort to reduce greenhouse gas emissions. A regulatory impact analysis prepared for the rule indicates 1400 excess deaths created per year by the rule.
Benralizumab Has No Effect on Influenza Vaccine Antibody Response, Study Finds
August 20th 2018

Benralizumab Has No Effect on Influenza Vaccine Antibody Response, Study Finds

David Bai
Benralizumab, an interleukin-5 (IL-5) antagonist used to treat severe asthma, does not weaken antibody response of influenza vaccinations, according to results of a recent study.
Study Probes How Severe Asthma Might Develop Through Allergic Inflammation
August 17th 2018

Study Probes How Severe Asthma Might Develop Through Allergic Inflammation

David Bai
A recent study discovered more about the immunological mechanisms correlated with lung inflammation in some severe asthma patients, raising possibilities it may serve as a baseline for future research and drug development.
FDA Gives Teva Green Light for First Generic EpiPen
August 17th 2018

FDA Gives Teva Green Light for First Generic EpiPen

Allison Inserro
The FDA cleared the first generic version of EpiPen and EpiPen Jr, an epinephrine auto-injector for severe allergic reactions, 2 years after generic drugmaker Teva Pharmaceuticals was first turned down in its bid to win approval for the device. The Teva device is the first-ever generic to the one marketed by Mylan, which is still in short supply during the busy back-to-school season in pharmacies due to production issues at Pfizer, which makes the device.
Lung Cancer Mortality Among Women Projected to Increase 43% by 2030, Study Finds
August 11th 2018

Lung Cancer Mortality Among Women Projected to Increase 43% by 2030, Study Finds

Alison Rodriguez
The global age-standardized lung cancer mortality rate among women is expected to increase by 43% from 2015 to 2030, while the global age-standardized breast cancer mortality rate is projected to decrease by 9%, according to an analysis published in Cancer Research.
<1
...
141516171819202122>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo